Observational studyStem cell reviews and reports2026
Circulating Biomarkers of Vascular Regeneration are not Associated with Residual Pulmonary Vascular Obstruction after Pulmonary Embolism: A Retrospective Observational Biomarker Study.
Observational study in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResidual pulmonary vascular obstruction (RPVO) persists in a substantial proportion of patients after acute pulmonary embolism (PE) despite adequate anticoagulation and is associated with long-term functional impairment. Angiogenesis plays a central role in thrombus resolution and vascular repair. In a recent prospective study, lower circulating CD34⁺ cell levels at follow-up were associated with the presence of RPVO, suggesting impaired regenerative and angiogenic capacity in patients with persistent perfusion defects. Whether classical circulating angiogenic biomarkers reflect this process remains unknown.
objectiveTo assess the relationship between angiogenic marker levels and the presence of RPVO ≥10% after an episode of PE. PATIENTS AND
methodsThis single-center retrospective study included patients diagnosed with acute PE who received at least three months of anticoagulant therapy between January 1999 and June 2006. During the follow-up consultation, performed 6-12 months after PE diagnosis, patients underwent a ventilation/perfusion lung scan, and peripheral blood sampling for plasma biobanking. Angiogenic markers (VEGF-A, FGF-2, PlGF, MMP-1, MMP-8, endoglin, and endostatin) were measured in plasma samples collected at this visit. Levels were compared between patients with a perfusion defect (RPVO ≥10%) and those without (RPVO <10%) on ventilation/perfusion scintigraphy.
resultsAmong 126 patients evaluated 6 to 12 months after a PE diagnosis, 39 (31%) had RPVO ≥10%. Median levels of VEGF-A, FGF-2, PlGF, MMP-1, MMP-8, endostatin, and endoglin did not significantly differ between patients with RPVO ≥10% and those with RPVO <10%.
conclusionNone of the angiogenic markers measured reflected the perfusion defect observed in patients.
Indexed as
Identifiers
42087023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.